Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition
MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Dec 2, 2008 - Gemin X Pharmaceuticals announced today that preclinical data from the company's targeted cancer therapy, obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor, will be presented in three oral sessions and two poster sessions during the 50th Annual American Society of Hematology (ASH) Meeting and Exposition in San Francisco December 6-9, 2008.
| Oral Session Title: | CD44 Signaling Via PI3K/AKT and MAPK/ERK Pathways Protects CLL Cells from Spontaneous and Drug Induced Apoptosis
|
|
| Abstract No: | 541 | |
| Program Date/Time: | Monday, December 8, 2008, 1:30 p.m. PT | |
| Location: | West Moscone Center, 2005-2007-2018-2020 | |
| Presenter: | Yair Herishanu, MD | |
| Oral Session Title: | The BH3-Mimetic Obatoclax (GX15-070) Possesses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin's Lymphoma (B-NHL) Cells
|
|
| Abstract No: | 605 | |
| Program Date/Time: | Monday, December 8, 2008: 4:30 p.m. PT | |
| Location: | West Moscone Center, 3006-3008 | |
| Presenter: | Francisco J. Hernandez-Ilizaliturri, MD | |
| Oral Session Title: | Effects of the Mcl-1/Bcl-2 Inhibitor GX15-070 (Obatoclax®) on Growth and Viability of Canine and Human Neoplastic Mast Cells
|
|
| Abstract No: | 861 | |
| Program Date/Time: | Tuesday, December 9, 2008: 8:15 a.m. PT | |
| Location: | San Francisco Marriott, Yerba Buena Ballroom Salon 8 | |
| Presenter: | Barbara Peter, MVM | |
| Poster Title: | The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways
|
|
| Abstract No. | 1633 | |
| Program Date/Time: | Saturday, December 6, 2008 | |
| Location: | Moscone Center, Hall A | |
| Presenter: | Yue Wei, PhD | |
| Poster Title: | Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias
|
|
| Abstract No: | 2647 | |
| Program Date/Time: | Sunday, December 7, 2008 | |
| Location: | Moscone Center, Hall A | |
| Presenter: | Alena Y. Zhang, PharmD, PhD |
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, to preclinical studies for its Telomere Capping program. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including elderly acute myeloid leukemia (AML), mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis. Founded in 1998, Gemin X is privately held with drug development and executive headquarters in Malvern, Pennsylvania and drug discovery operations in Montréal, Canada. For more information, please visit www.geminx.com.
Contact: Pure Communications
Keri P. Mattox, 215-791-0105
